drugset

drugset / Trial / NCT04690595

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

NCT04690595 ↗

Phase 1 Active not recruiting 24 enrolled PeproMene Bio, Inc. City of Hope Medical Center · collab

NaSingle-groupOpen-labelTreatment

Summary

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Timeline

Start: 2021-05-18
Primary completion: 2026-11-18
Completion: 2027-11-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BAFFR-CAR T cells	Cell therapy	—	—

Indications